Acquisition of a Q-TOF Mass Spectrometer
Acquisition of a Q-TOF Mass Spectrometer
批准号:
8246986
负责人:
WEI LI
金额:
$32.5万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-05-01 至 2013-04-30
关键词:
18 year oldAdvisory CommitteesAgeAreaBacteriaBiomedical ResearchChargeCommitCost SharingDevelopmentDiabetes MellitusDiseaseDrug Delivery SystemsEnsureEquus caballusFeesFundingFutureHealth SciencesInflammationInnovative TherapyLicensingMaintenanceMalignant NeoplasmsMolecularObesityPharmacologic SubstancePharmacy facilityPhase III Clinical TrialsPrincipal InvestigatorRadiationRadiation ProtectionRequest for ApplicationsResearch PersonnelScienceScientistSourceStagingStructureSystemTennesseeTranslationsUnited States National Institutes of HealthUniversitiesWorkcollegecostdrug candidatedrug discoveryinstrumentliquid chromatography mass spectrometrymass spectrometernovelpre-clinicalprogramsrepairedsmall molecule
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): This application requests funding to acquire a Q-TOF mass spectrometer to replace the mass spectrometer component of an 18-year-old Bruker Esquire-LC/MS system, which is an essential part of the Shared Instrument Facility in the Department of Pharmaceutical Sciences at the University of Tennessee Health Science Center (UTHSC). The Bruker Esquire-LC/MS system has been well maintained and is the work horse supporting extensive small-molecular drug discovery and drug delivery programs at UTHSC in the areas of cancer, obesity, diabetes, radiation protection, radiation mitigation, bacteria inflection, and inflammation diseases. Several small-molecule drug candidates have been licensed for commercial development, including one currently in Phase III clinical trials. However, the age of the current mass spectrometer has resulted in more and more frequent breakdowns in recent years. Bruker officially stopped technical support for this type of instrument system in early 2010. Repair parts are scarce and have become very expensive. The proposed new Q-TOF mass spectrometer will replace the now unreliable mass spectrometer component of the Bruker Esquire-LC/MS system. This powerful new mass spectrometer will benefit more than 10 principal investigators supported by nine R01s, one RC2, one R33, three R21s, and other sources of support. The Q-TOF mass spectrometer will provide years of reliable accessibility, greater sensitivity in both MS and MS/MS modes, and the capability to obtain accurate mass for more efficient structure elucidation. This state-of-the-art instrument wil support drug discovery in preclinical development by using novel small molecules and their translation to innovative therapies for a variety of diseases. UTHSC is strongly committed to supporting biomedical research. The College of Pharmacy will provide $25,000 as a cost share for the purchase of the new instrument, fully support a staff scientist to maintain the Shared Instrument Facility, and assume all future maintenance and repair cost after the warranty period without charging user fees. An advisory committee will ensure effective utilization of the instrument and adequate access by the major users, other NIH-supported investigators, new investigators, and investigators with early-stage projects.
PUBLIC HEALTH RELEVANCE: The Q-TOF mass spectrometer requested will replace a technologically limited Esquire-LC/MS mass spectrometer that is nearly two decades old and will provide reliable and sophisticated support for 20 currently funded projects important to human health. These projects focus on small-molecule drug discovery and drug delivery in the areas of cancer, obesity, diabetes, radiation protection, radiation mitigation, bacteria inflection and inflammation diseases.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1002/pca.2517
发表时间:
2014-11
期刊:
Phytochemical analysis : PCA
影响因子:
--
作者:
[Lin Z, Yang R, Guan Z, Chen A, Li W]
通讯作者:
Li W
Targeting brain and bone metastases in metastatic breast cancer for improved patient survival
-
批准号:10564604
-
项目类别:
-
资助金额:$61.49万
-
财政年份:2023
-
负责人:WEI LI
-
依托单位:
Developing a selective TRPC3 ion channel inhibitor for epilepsy treatment
-
批准号:10819354
-
项目类别:
-
资助金额:$42.99万
-
财政年份:2023
-
负责人:WEI LI
-
依托单位:
Dual inhibition of MDM2 and XIAP as a therapeutic strategy in cancer
-
批准号:10224705
-
项目类别:
-
资助金额:$54.15万
-
财政年份:2020
-
负责人:WEI LI
-
依托单位:
Dual inhibition of MDM2 and XIAP as a therapeutic strategy in cancer
-
批准号:10652443
-
项目类别:
-
资助金额:$53.07万
-
财政年份:2020
-
负责人:WEI LI
-
依托单位:
Selective Targeting Survivin for Cancer Therapy
-
批准号:9922228
-
项目类别:
-
资助金额:$38.01万
-
财政年份:2016
-
负责人:WEI LI
-
依托单位:
Selective Targeting Survivin for Cancer Therapy
-
批准号:9254523
-
项目类别:
-
资助金额:$38.01万
-
财政年份:2016
-
负责人:WEI LI
-
依托单位:
Discovery of tissue-selective, nonhypercalcemic VDR modulators for RA treatment
-
批准号:8511162
-
项目类别:
-
资助金额:$15.94万
-
财政年份:2013
-
负责人:WEI LI
-
依托单位:
Discovery of Novel Thiazole Analogs for Treating Malignant Melanoma
-
批准号:8403695
-
项目类别:
-
资助金额:$28.87万
-
财政年份:2011
-
负责人:WEI LI
-
依托单位:
Discovery of Novel Thiazole Analogs for Treating Malignant Melanoma
-
批准号:8589375
-
项目类别:
-
资助金额:$29.79万
-
财政年份:2011
-
负责人:WEI LI
-
依托单位:
Targeting the colchicine binding site in tubulin for cancer therapy
-
批准号:10298280
-
项目类别:
-
资助金额:$40.33万
-
财政年份:2011
-
负责人:WEI LI
-
依托单位:
Discovery of Novel Thiazole Analogs for Treating Malignant Melanoma
-
批准号:8041517
-
项目类别:
-
资助金额:$30.71万
-
财政年份:2011
-
负责人:WEI LI
-
依托单位:
Targeting the colchicine binding site in tubulin for cancer therapy
-
批准号:10680394
-
项目类别:
-
资助金额:$38.98万
-
财政年份:2011
-
负责人:WEI LI
-
依托单位:
Targeting the colchicine binding site in tubulin for cancer therapy
-
批准号:10458768
-
项目类别:
-
资助金额:$38.2万
-
财政年份:2011
-
负责人:WEI LI
-
依托单位:
Discovery of Novel Thiazole Analogs for Treating Malignant Melanoma
-
批准号:8207242
-
项目类别:
-
资助金额:$30.71万
-
财政年份:2011
-
负责人:WEI LI
-
依托单位:
Discovery of Novel Thiazole Analogs for Treating Malignant Melanoma
-
批准号:8787452
-
项目类别:
-
资助金额:$30.71万
-
财政年份:2011
-
负责人:WEI LI
-
依托单位:
Targeting the colchicine site in tubulin for advanced melanoma
-
批准号:9033412
-
项目类别:
-
资助金额:$39.14万
-
财政年份:2011
-
负责人:WEI LI
-
依托单位:
Acquisition of a 400MHz Solution NMR System with an Autosampler
-
批准号:7790824
-
项目类别:
-
资助金额:$25.29万
-
财政年份:2010
-
负责人:WEI LI
-
依托单位:
Discovery of Novel Cytotoxic Agents for Advanced Melanoma
-
批准号:7458255
-
项目类别:
-
资助金额:$21.9万
-
财政年份:2008
-
负责人:WEI LI
-
依托单位:
Novel rod and blue cone signaling pathways in the retina
-
批准号:7212253
-
项目类别:
-
资助金额:$1.89万
-
财政年份:2006
-
负责人:WEI LI
-
依托单位:
Novel rod and blue cone signaling pathways in the retina
-
批准号:7052267
-
项目类别:
-
资助金额:$4.88万
-
财政年份:2006
-
负责人:WEI LI
-
依托单位:
海外基金